Supercharge Your Innovation With Domain-Expert AI Agents!

Tumor immunotherapy method

A tumor, solid tumor technology, applied in the field of tumor treatment, can solve the problem of not showing a completely satisfactory effect on anti-tumor

Inactive Publication Date: 2018-10-23
张晋宇
View PDF0 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Cytokines cover a large number of various proteins. So far, none of the cytokines or their combinations that have been used have shown a completely satisfactory effect in anti-tumor

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Tumor immunotherapy method
  • Tumor immunotherapy method
  • Tumor immunotherapy method

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0088] Example 1. Therapeutic effect of mIL12+mGMCSF+mIL2 chitosan quaternary ammonium salt solution on mouse melanoma

[0089] Digestion of cultured mouse melanoma cells (B16F10), 2 × 10 5 The cells were injected subcutaneously into the right side of the C57BL / 6 mouse body, and the treatment was started when the length of the tumor reached about 7-9 mm.

[0090] The cytokines mIL12, mGMCSF and mIL2 were dissolved in sterile water to make the final concentration of 20ng / µl, and 15µl of each was mixed to obtain a mixture of 45µl mIL12+mGMCSF+mIL2, and then pre-configured 3% chitosan was added. 45µl of sugar quaternary ammonium salt solution, mix by carefully pipetting with a pipette tip. The tumor-bearing mice were anesthetized by intraperitoneal injection of sodium pentobarbital, and then the prepared cytokine chitosan quaternary ammonium salt solution was drawn with a 29G insulin syringe, and slowly injected into the tumor. Spill of solution. After the injection, the mice ...

Embodiment 2

[0092] Example 2. Therapeutic effect of mIL12+mGMCSF+mIL2 chitosan quaternary ammonium salt solution on mouse colon cancer

[0093] Cultured mouse colon cancer cells (CT26) were digested and 5 × 10 5 The cells were injected subcutaneously on the right side of Balb / c mice, and the treatment was started when the length of the tumor reached about 7-9 mm.

[0094] The cytokines mIL12, mGMCSF and mIL2 were dissolved in sterile water to make the final concentration of 20ng / µl, and 15µl of each was mixed to obtain a mixture of 45µl mIL12+mGMCSF+mIL2, and then pre-configured 3% chitosan was added. 45µl of sugar quaternary ammonium salt solution, mix by carefully pipetting with a pipette tip. The tumor-bearing mice were anesthetized by intraperitoneal injection of sodium pentobarbital, and then the prepared cytokine chitosan quaternary ammonium salt solution was drawn with a 29G insulin syringe, and slowly injected into the tumor. Spill of solution. After the injection, the mice wer...

Embodiment 3

[0096] Example 3. Therapeutic effect of mIL12+mGMCSF+mIL2 chitosan quaternary ammonium salt solution on mouse breast cancer

[0097] Digestion of cultured mouse breast cancer cells (4T1), 2 × 10 5 The cells were injected subcutaneously on the right side of Balb / c mice, and the treatment was started when the length of the tumor reached about 7-9 mm.

[0098] Dissolve cytokines mIL12, mGMCSF and mIL2 with sterile water to make the final concentration of 20ng / µl, take 15µl of each and mix to obtain 45µl of mIL12+mGMCSF+mIL2 mixture, then add pre-configured 3% chitosan 45µl of sugar quaternary ammonium salt solution, mix by carefully pipetting with a pipette tip. The tumor-bearing mice were anesthetized by intraperitoneal injection of sodium pentobarbital, and then the prepared cytokine chitosan quaternary ammonium salt solution was drawn with a 29G insulin syringe, and slowly injected into the tumor. Spill of solution. After the injection, the mice were put back into the cage ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of tumor treatment, particularly to a tumor immunotherapy method for treating tumors and / or preventing tumor recurrence or metastasis through intratumoral administration with a specific cytokine combination, and a corresponding pharmaceutical composition.

Description

technical field [0001] The present invention relates to the field of tumor treatment. In particular, the present invention relates to tumor immunotherapy and corresponding pharmaceutical compositions for intratumoral administration of specific cytokine combinations to treat tumors and / or prevent tumor recurrence or metastasis. Background technique [0002] Tumor is a disease that seriously threatens human health and brings huge social and economic problems. Traditional treatment methods include radiotherapy, chemotherapy, surgery, and targeted drug therapy. In recent years, immunotherapy, as a new therapy, has shown great potential in tumor treatment. [0003] The most important tumor immunotherapy methods at this stage include chimeric antigen receptor T cell therapy (CAR-T) and immune checkpoint therapy (Checkpoint). The former transforms T cells so that they can more accurately and effectively identify and kill tumor cells in the body. Immune checkpoints use antibody ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/20A61P35/00A61P35/04A61K38/19
CPCA61K38/19A61K38/193A61K38/20A61K38/2013A61K38/208A61K38/2086A61K2300/00A61P35/00A61P35/04A61K9/0014A61K38/00C07K14/52C07K14/535C07K14/54C07K14/5418C07K14/5434C07K14/5443C07K14/55
Inventor 不公告发明人
Owner 张晋宇
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com